timothy sykes logo

Stock News

Soleno Therapeutics Stock Soars: Could FDA Update Signal a Promising Future?

Timothy SykesAvatar
Written by Timothy Sykes Reviewed by Jack Kellogg Fact-checked by Ellis Hobbs

Amid strong positive sentiment, Soleno Therapeutics Inc.’s stock is significantly influenced by their announcement of impressive late-stage clinical trial results for a novel obesity treatment, leading to increased investor confidence. On Friday, Soleno Therapeutics Inc.’s stocks have been trading up by 13.15 percent.

Core News Insights

  • The FDA gave a positive nudge to Soleno Therapeutics, suggesting no advisory committee meeting is needed just yet for their drug DCCR, aimed at tackling Prader-Willi syndrome, leading to a tangible lift in stock prices.

Candlestick Chart

Live Update at 16:03:31 EST: On Friday, October 11, 2024 Soleno Therapeutics Inc. stock [NASDAQ: SLNO] is trending up by 13.15%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

  • Stifel’s analyst, Dae Gon Ha, sees clear skies, raising the price target for Soleno to $74, while emphasizing market exclusivity for DCCR as a buoyant long-term value creator.

  • DCCR’s ongoing FDA review, marked with a Priority Review tag, targets a decision close to the year’s end, hinting much-anticipated market dynamism.

Quick Overview of Soleno’s Financial Landscape

Peeling back the financial layers of Soleno reveals an intriguing narrative. At first glance, their financial metrics exhibit a race against time. With an enterprise value approximating $1.48B, expectations are steep. However, certain financial metrics like Price to Book at 7.02, pose a hefty price tag for revenue generation.

The income sheet showcases an operational loss with EBITDA at -$20.89M. Despite the net income tumbling to -$21.85M, a downbeat melody doesn’t play across the board. The persistence in research expenses, touching $12.34M, signifies a relentless quest for breakthroughs, particularly in the development of DCCR.

On a brighter financial note, the essential financial paddles—current and quick ratios—are sturdy at 36.7 and 36.5, respectively. As such, liquidity seems less of a worry, potentially providing a cushion to brave unforeseen economic squalls.

More Breaking News

Let’s flux between balance sheets and cash flow dynamics. A cash position of $57.02M might not trigger celebratory fireworks, but strategic stock issuance worth $148.96M plugs essential operational gaps. With an operational cash flow depleting around -$17.7M, the company is keenly eyeing future revenues from its market-focused endeavors.

DCCR and its Market Proposition

DCCR (Diazoxide Choline Controlled Release) remains the flagship warrior poised to combat Prader-Willi syndrome-related battles in the pharmaceutical arena. As the FDA review proceeds, the drug receives a lifeline through speculation. The recent nod quashing an immediate advisory committee setup can be seen as a beacon of hope, casting ripples across investor pools seeking promising avenues.

Such pivotal news not only stabilizes share price but also serves as a clarion call to potential exclusivity rights. The concept of adding DCCR-related patents to the coveted Orange Book list elevates Soleno’s aspirations within the biopharma hierarchy, injecting optimism and confidence among stakeholders.

Market Prospects Amidst Regulatory Hurdles

Navigating next steps in the vast marketing ocean, Soleno might get swayed neither by rapid currents nor by lurking legal tempests. Instead, they focus on balancing precarious outcomes, reflected by maintaining dialogues with regulatory giants like the FDA. This blend of strategic financial maneuvering and calculated advancements churns out an intriguing investment cocktail with complex flavor notes.

In the realm of stock trajectory, numbers mumble an enigmatic tale. The stock witnessed a $7.37 surge, settling with a bullish undertone at $55. It’s akin to spotting a promising lighthouse amidst foggy waters, redirecting attention to prospective financial gains.

Concluding Thoughts

Each calculated move by Soleno Therapeutics is reminiscent of a strategic chess play. By fostering innovation and showcasing resilience, particularly through their ongoing DCCR trials, they solidify their standing as a forerunner in the small-cap biotech niche.

The recent cascade of news acts as steroids, fueling investor sentiment and cultivating an optimistic roadmap for Soleno’s future stock performance. While the company wades through ferocious industry currents, their compass seems set for growth, steered by robust scientific advancements and keen market acumen.

For those craning their necks for potential profit, the meld of current financial and market insights suggests Soleno Therapeutics might be sailing towards fruitful shores, albeit with caution always ringing its subtle alarm.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Our traders will never trade any stock until they see a setup they like. Their strategy is to capture short-term momentum while avoiding undue risk exposure to a stock’s long-term volatility. This method is especially useful when trading penny stocks or other high-risk equities, where rapid gains can be made by understanding stock patterns, manipulation, and media hype. Whether you are an active day trader looking for key indicators on a stock’s next move, or an investor doing due diligence before entering a position, Timothy Sykes News is designed to help you make informed trading decisions.

Curious about this stock and eager to learn more? Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success. Start your journey towards financial growth and trading mastery!

But wait, there’s more! Elevate your trading game with StocksToTrade, the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade harnesses the power of Artificial Intelligence to guide you through the market’s twists and turns. Discover insights on Robinhood penny stocks and top biotech picks to fuel your trading journey:

Ready to embark on your financial adventure? Click the links and let the journey unfold.

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Timothy Sykes

Tim Sykes is a penny stock trader and teacher who became a self-made millionaire by the age of 22 by trading $12,415 of bar mitzvah money. After becoming disenchanted with the hedge fund world, he established the Tim Sykes Trading Challenge to teach aspiring traders how to follow his trading strategies. He’s been featured in a variety of media outlets including CNN, Larry King, Steve Harvey, Forbes, Men’s Journal, and more. He’s also an active philanthropist and environmental activist, a co-founder of Karmagawa, and has donated millions of dollars to charity. Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”